# RARE — Ultragenyx Pharmaceutical Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** RARE  
**Sources:** 29  
**Published:** 2026-10-14  
**Canonical:** https://app.k3vl4r.com/research/deep-research-rare-ultragenyx-pharmaceutical-inc-catalysts-narrative-r-7394

---

## Overview

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a rare-disease biopharmaceutical company headquartered in Novato, California, commercializing and developing therapies for ultra-rare genetic diseases across multiple modalities (biologics, small molecules, gene therapy, ASO) [[24]](https://finance.yahoo.com/quote/RARE/), [[28]](https://en.wikipedia.org/wiki/Ultragenyx). As of mid-October 2026 the stock trades near its 52-week lows (~$14.50–14.89) after a sharp decline, and its market capitalization has compressed from roughly $2.5 billion in late August [[5]](https://hatedmoats.substack.com/p/ultragenyx-rare-a-catalyst-driven) to around $1.47 billion by mid-October [background]. Below I focus on the last ~1–3 months.

## Recent catalysts (July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-rare-ultragenyx-pharmaceutical-inc-catalysts-narrative-r-7394 (free to sign up)._